GSK Stock Forecast for 2023 - 2025 - 2030

Updated on 12/07/2023

Stock Rating
12
Price Target
£16.20
Consensus
Outperform
Upside
12.50%
Analysts
16
Stock Rating
12
Upside
12.50%
Analysts
16
Price Target
£16.20

GSK Stock Forecast and Price Target

The average price target of £16.20 for GSK's stock set by sixteen distinguished analysts in recent weeks would represent a potential upside of approximately 12.5% from the last closing price in December, 2023 if reached by the end of the year. This potential increase is based on a high estimate of £25.30 and a low estimate of £11.90. If you are not interested in GSK stock, you may be interested in its competitors.

£16.20

12.50% Upside

Outperform
Outperform

GSK Fair Value Forecast for 2023 - 2025 - 2030

GSK's Price has decreased In the last three years, from £18.79 to £16.97 – a 9.68% drop. In the next year, analysts believe that Fair Value will reach £18.54 – an increase of 9.29%. For the next eight years, the forecast is for Fair Value to grow by 23.57%.

2023 Fair Value Forecast
£18.54
2024 Fair Value Forecast
£18.91
2025 Fair Value Forecast
£21.09
2026 Fair Value Forecast
£23.39
2027 Fair Value Forecast
£24.97
2028 Fair Value Forecast
£22.66
2029 Fair Value Forecast
£21.45
2030 Fair Value Forecast
£20.97
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 10
$146.38 Buy/Sell $167.35 14.09%
AZN Stock Forecast AstraZeneca PLC Buy 17
£101.30 Buy/Sell £169.00 59.63%
ABT Stock Forecast Abbott Laboratories Outperform 10
$104.94 Buy/Sell $116.25 9.87%
AMGN Stock Forecast Amgen Inc Outperform 7
$269.35 Buy/Sell $276.06 6.55%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$49.88 Buy/Sell $64.13 23.30%

GSK Revenue Forecast for 2023 - 2025 - 2030

GSK's Revenue has decreased In the last three years, from £33.75B to £29.32B – a 13.12% drop. In the next year, analysts believe that Revenue will reach £29.62B – an increase of 1.00%. For the next eight years, the forecast is for Revenue to grow by 17.07%.

2023 Rev Forecast
£29.62B
2024 Rev Forecast
£31.19B
2025 Rev Forecast
£33.08B
2026 Rev Forecast
£35.11B
2027 Rev Forecast
£36.42B
2028 Rev Forecast
£37.38B
2029 Rev Forecast
£34.99B
2030 Rev Forecast
£34.33B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$79.36 Buy/Sell $90.39 14.04%
CSL Stock Forecast CSL Outperform 12
$267.47 Buy/Sell $207.22 -24.35%
BDX Stock Forecast Becton Dickinson and Co Outperform 9
$233.45 Buy/Sell $301.27 19.94%

GSK Dividend per Share Forecast for 2023 - 2025 - 2030

In the last three years, GSK's Dividend per Share has seen a drop from £1.00 to £0.61 – a 39.00% decrease. According to 16 major analysts, GSK's Dividend per Share will fall by 6.56% in the next year, reaching £0.57. For the next eight years, experts predict that GSK's Dividend per Share will grow at a rate of 7.60%.

2023 DPS Forecast
£0.57
2024 DPS Forecast
£0.61
2025 DPS Forecast
£0.65
2026 DPS Forecast
£0.66
2027 DPS Forecast
£0.68
2028 DPS Forecast
£0.66
2029 DPS Forecast
£0.65
2030 DPS Forecast
£0.66
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CL Stock Forecast Colgate-Palmolive Co Outperform 18
$77.47 Buy/Sell $81.66 8.43%
MMM Stock Forecast 3M Co Hold 10
$102.79 Buy/Sell $110.96 4.10%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.21k Buy/Sell ¥0.00 28.21%

GSK Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, GSK's Free Cash Flow has fallen from £6.76B to £6.23B – a 7.76% decrease. According to 5 analysts, GSK's Free Cash Flow will fall by 10.77% in the next year, reaching £5.56B. Over the next eight years, experts believe that GSK's Free Cash Flow will grow at a rate of 65.17%.

2023 FCF Forecast
£5.56B
2024 FCF Forecast
£6.63B
2025 FCF Forecast
£7.29B
2026 FCF Forecast
£7.50B
2027 FCF Forecast
£7.98B
2028 FCF Forecast
£9.49B
2029 FCF Forecast
£9.92B
2030 FCF Forecast
£10.29B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABEV3 Stock Forecast Ambev Outperform 18
R$13.99 Buy/Sell R$15.81 16.15%
BN Stock Forecast Danone Hold 18
58.72€ Buy/Sell 55.47€ -3.10%
ADM Stock Forecast Archer-Daniels-Midland Co Outperform 4
$73.19 Buy/Sell $91.17 22.97%

GSK Net Income Forecast for 2023 - 2025 - 2030

GSK's Net Income has seen impressive growth In the last three years, rising from £4.65B to £14.96B – a growth of 221.98%. In the next year, 15 analysts estimate that GSK's Net Income will decrease by 58.25%, reaching £6.24B. According to professional forecasts, in 2030, GSK's Net Income will decrease by 52.81%, reaching £7.06B.

2023 NI Forecast
£6.24B
2024 NI Forecast
£6.39B
2025 NI Forecast
£7.15B
2026 NI Forecast
£7.69B
2027 NI Forecast
£8.07B
2028 NI Forecast
£7.60B
2029 NI Forecast
£7.19B
2030 NI Forecast
£7.06B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALC Stock Forecast Alcon Outperform 15
CHF63.20 Buy/Sell CHF0.00 42.03%
A Stock Forecast Agilent Technologies Outperform 17
$128.91 Buy/Sell $132.86 4.72%
4519 Stock Forecast Chugai Pharmaceutical Outperform 18
¥5.44k Buy/Sell ¥0.00 -6.25%

GSK EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, GSK's EBITDA has decreased from £10.32B to £9.47B – a 8.26% drop. In the next year, analysts predict that EBITDA will jump to £10.24B – up 8.18% from the current level. Looking ahead to eight years, experts forecast that EBITDA will grow by 59.76%.

2023 EBITDA Forecast
£10.24B
2024 EBITDA Forecast
£10.62B
2025 EBITDA Forecast
£11.52B
2026 EBITDA Forecast
£12.50B
2027 EBITDA Forecast
£13.20B
2028 EBITDA Forecast
£13.97B
2029 EBITDA Forecast
£14.55B
2030 EBITDA Forecast
£15.13B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
32.39€ Buy/Sell 55.86€ 38.93%
BEI Stock Forecast Beiersdorf Outperform 17
131.75€ Buy/Sell 131.91€ 6.26%
CTVA Stock Forecast Corteva Outperform 12
$44.15 Buy/Sell $59.82 34.77%

GSK EBIT Forecast for 2023 - 2025 - 2030

In the last three years, GSK's EBIT has decreased by 10.72%, going from £8.20B to £7.32B. Analysts predict that GSK's EBIT will increase in the upcoming year, reaching £8.68B. This would represent an increase of 18.57%. Over the next eight years, experts predict that GSK's EBIT will grow at a rate of 34.92%.

2023 EBIT Forecast
£8.68B
2024 EBIT Forecast
£9.15B
2025 EBIT Forecast
£10.08B
2026 EBIT Forecast
£11.14B
2027 EBIT Forecast
£11.41B
2028 EBIT Forecast
£10.84B
2029 EBIT Forecast
£10.38B
2030 EBIT Forecast
£9.88B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
HEN3 Stock Forecast Henkel AG & Co. KGaA Hold 16
72.80€ Buy/Sell 71.63€ -0.41%
COLO B Stock Forecast Coloplast A/S Outperform 18
kr777.60 Buy/Sell kr841.28 3.52%
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.81k Buy/Sell ¥0.00 38.16%

GSK EPS Price Prediction Forecast for 2023 - 2025 - 2030

GSK's EPS has decreased In the last three years, from £1.55 to £1.40 – a 9.68% drop. In the next year, analysts believe that EPS will reach £1.53 – an increase of 9.29%. For the next eight years, the forecast is for EPS to grow by 23.57%.

2023 EPS Forecast
£1.53
2024 EPS Forecast
£1.56
2025 EPS Forecast
£1.74
2026 EPS Forecast
£1.93
2027 EPS Forecast
£2.06
2028 EPS Forecast
£1.87
2029 EPS Forecast
£1.77
2030 EPS Forecast
£1.73
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CHD Stock Forecast Church & Dwight Co Inc Hold 11
$93.53 Buy/Sell $95.97 2.11%
HOLX Stock Forecast Hologic Outperform 8
$69.11 Buy/Sell $79.88 13.59%
4523 Stock Forecast Eisai Outperform 18
¥7.52k Buy/Sell ¥0.00 24.29%